currently available KCNN4 blockers might therefore attenuate tissue fibrosis and remodeling in patients with diseases such as idiopathic pulmonary fibrosis and asthma through the inhibition of fibrocyte recruitment
it may be possible to rapidly test whether KCa3.1 inhibitors are efficacious in patients with inflammatory bowel diseases such as Crohn disease and ulcerative colitis
CKCNN4 blockers represent a promising therapeutic strategy for atherosclerosis.
chronic kidney disease
pharmacological inhibitors of KCNN4 channels may provide a novel and effective therapy to delay progression to kidney failure in patients with ADPKD